Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal
September 6th, 2022 | 🕒
iSpeech.org Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload) Emergence Therapeutics secures rights
Gloss